PRP remains one of the most extensively studied orthobiologics in musculoskeletal medicine. Research has investigated its application across osteoarthritis, tendinopathies, ligament injuries, and other conditions, with many studies reporting improvements in pain and function.
At the same time, researchers have recognized that PRP is not a single standardized treatment. A 2019 review examining commercially available PRP systems found substantial differences in platelet concentration and preparation methods between systems. These findings have helped highlight the importance of better characterization and standardization as the field continues to develop. (pubmed.ncbi.nlm.nih.gov)
In other words, the question is becoming less about “Does PRP work?” and more about “Which PRP preparation, for which patient, and for which condition?”
That distinction could ultimately lead to more precise treatment protocols.
Research has also expanded into biologics containing cellular and tissue-derived components.
BMAC, for example, contains mesenchymal stromal/stem cells along with other cellular and signaling components derived from bone marrow. Clinical research has investigated its potential in conditions including knee osteoarthritis and cartilage-related pathology.
A 2025 systematic review found that BMAC was associated with improvements in clinical outcomes across the available literature, while also identifying opportunities to better define treatment protocols and patient selection. (pubmed.ncbi.nlm.nih.gov)
Similarly, research into microfragmented adipose tissue (MFAT) has expanded rapidly. A randomized controlled trial comparing MFAT and PRP for knee osteoarthritis found improvements in patient-reported outcomes with both treatments over 12 months. (pubmed.ncbi.nlm.nih.gov)
Rather than establishing a single superior biologic, these studies contribute to a larger body of evidence exploring which biologic characteristics may be most relevant to different clinical situations.
One of the most interesting developments in orthobiologic research is the increasing focus on what is actually contained within the treatment being administered.
For example, PRP preparations can differ in platelet and leukocyte concentrations. BMAC contains a combination of cellular and non-cellular components. Adipose-derived therapies contain their own distinct cellular and extracellular components.
Understanding these differences may help researchers determine why two patients receiving treatments that are broadly categorized under the same name can experience different outcomes.
This is where standardization becomes an opportunity rather than simply a limitation.
Better characterization of biologic products could eventually allow researchers to establish more precise relationships between biologic composition, patient characteristics, diagnosis, dose, and clinical outcome.
The research landscape is also expanding beyond PRP and BMAC.
Platelet lysate is one example. A 2024 review of the clinical evidence identified studies reporting improvements in pain and function among patients with knee osteoarthritis while also highlighting the need for larger and longer-term investigations. (pubmed.ncbi.nlm.nih.gov)
These emerging therapies represent an important direction for the field: understanding whether different biologic preparations may have different applications based on the tissue, pathology, and biological environment being treated.
As research continues, the goal is not necessarily to find one biologic that replaces all others. It may instead be to understand which biologic is best suited to a particular clinical problem.
This concept of individualized treatment is increasingly reflected in Dr. Vivek Babaria's approach to orthobiologics.
Dr. Babaria has described the principles of precision orthobiologics as:
“Right patient, right diagnosis, right dose, right time, right injectate.”
That framework reflects an important direction in the field. The future of regenerative medicine may depend not only on developing new biologics, but also on improving our ability to match a specific treatment to the biological and clinical characteristics of an individual patient.
Dr. Babaria has also discussed the importance of collecting standardized clinical data and characterizing the biologics being administered. In a Becker's Hospital Review interview, he described an initiative involving multiple centers designed to capture orthobiologic treatments alongside patient-reported outcomes and characteristics of the substances being injected.
As he explained:
“Having this information and understanding its correlation to patient reported outcomes might help us to nearly customize how we think about the use of orthobiologics in the future.”
That idea represents an important transition in regenerative medicine—from broad treatment categories toward data-driven personalization.
The next generation of regenerative medicine research will likely focus increasingly on questions of precision.
Which patients respond best to PRP?
Which characteristics of a biologic influence treatment response?
When might BMAC or adipose-derived therapies be appropriate?
How should biologic treatments be dosed and standardized?
Can patient-specific factors help predict outcomes?
These questions don't diminish the potential of regenerative medicine. They represent the next stage of its development.
As the evidence base grows, the field has the opportunity to move from broad treatment categories toward increasingly individualized orthobiologic protocols.
For physicians actively involved in regenerative medicine, that evolution means not simply following the literature, but contributing to the research needed to answer the questions that remain.
The future of orthobiologics may not be about finding one “best” treatment. It may be about developing a more precise understanding of the right treatment for the right patient, at the right time.
